Investment Thesis
West Pharmaceutical demonstrates solid financial stability with a fortress balance sheet, minimal debt (D/E: 0.07x), and healthy operating margins (21%), but is hampered by concerning profitability stagnation where net income growth of 0.2% significantly lags revenue growth of 6.3%. Critical weaknesses in capital efficiency (ROE: 4.6%, ROA: 3.4%) and a substantial gap between net income ($138.8M) and operating cash flow ($89.9M) suggest underlying operational challenges or working capital deterioration that warrant monitoring.
Strengths
- Fortress balance sheet with minimal leverage (D/E 0.07x) and $521.4M cash position providing strategic flexibility
- Strong liquidity ratios (2.71x current, 2.04x quick) and excellent interest coverage (11.7x) indicate zero financial distress risk
- Healthy absolute margins: 35.1% gross margin and 21.0% operating margin demonstrate pricing power in medical devices sector
Risks
- Profitability growth has stalled (net income +0.2%, EPS +1.5%) despite 6.3% revenue growth, indicating margin compression or operational deleverage
- Exceptionally low returns on capital (ROE 4.6%, ROA 3.4%) signal severe capital inefficiency and question long-term value creation
- Operating cash flow of $89.9M significantly lags net income of $138.8M, revealing working capital drag or earnings quality concerns
Key Metrics to Watch
- Earnings growth trajectory relative to revenue growth to confirm margin recovery
- Return on equity and asset returns trends indicating capital deployment effectiveness
- Operating cash flow to net income conversion ratio for cash quality assessment
Financial Metrics
Revenue
844.9M
Net Income
138.8M
EPS (Diluted)
$1.92
Free Cash Flow
47.2M
Total Assets
4.1B
Cash
521.4M
Profitability Ratios
Gross Margin
35.1%
Operating Margin
21.0%
Net Margin
16.4%
ROE
4.6%
ROA
3.4%
FCF Margin
5.6%
Balance Sheet & Liquidity
Current Ratio
2.71x
Quick Ratio
2.04x
Debt/Equity
0.07x
Debt/Assets
27.2%
Interest Coverage
11.73x
Long-term Debt
202.8M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-29T15:27:50.950423 |
Data as of: 2026-03-31 |
Powered by Claude AI